Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

This phase II trial studies the effects of temozolomide and atezolizumab as second or third line treatment for patients with small cell lung cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells t

Trial Details

NCT ID
NCT04919382
Phase
PHASE2
Sponsor
Dwight Owen
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • Atezolizumab
  • Temozolomide
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Iowa City, Iowa, United States|41.66113,-91.53017
  • Columbus, Ohio, United States|39.96118,-82.99879
  • Madison, Wisconsin, United States|43.07305,-89.40123

Key Eligibility Criteria

  • Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information
  • NOTE: HIPAA authorization may be included in the informed consent or obtained separately
  • Age \>= 18 years at the time of consent
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2 within 28 days prior to registration

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →